According to an article in USA Today, Lilly USA will eliminate approximately 485 jobs across the United States after the failure of an Alzheimer's drug, solanezumab.
The company said 75 employees in Indiana, where Lilly's subsidiary has its headquarters, will be affected, according to the Indiana Department of Workforce Development. In December, Lilly announced that trials showed the drug did not achieve its goal and layoffs would be forthcoming.
Lilly said it was closing its Integrated Health Partners/Cardiovascular Account Specialists department, part of its Bio-Medicine Business Unit.
Read the USA Today article